Israel Englander Cyclacel Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.52 - $0.76 $35,384 - $51,716	-68,048 Reduced 57.11%	51,110 $30,000
Q1 2023 May 15, 2023	SELL	$0.56 - $1.15 $49,786 - $102,239	-88,904 Reduced 42.73%	119,158 $68,000
Q4 2022 Feb 14, 2023	BUY	$0.54 - $21.75 $6,813 - $274,419	12,617 Added 6.46%	208,062 $139,000
Q3 2022 Nov 14, 2022	BUY	$1.23 - $21.9 $111,932 - $1.99 Million	91,002 Added 87.13%	195,445 $285,000
Q2 2022 Aug 15, 2022	BUY	$6.1 - $7.15 $637,102 - $746,767	104,443 New	104,443 $113,000
Q1 2022 May 16, 2022	SELL	$5.93 - $7.6 $59,851 - $76,706	-10,093 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$6.04 - $8.03 $60,961 - $81,046	10,093 New	10,093 $39,000
Q3 2020 Nov 16, 2020	SELL	$4.81 - $6.49 $236,656 - $319,314	-49,201 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.2 - $7.75 $255,845 - $381,307	49,201 New	49,201 $229,000

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $5.27M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.